Results 71 to 80 of about 46,290 (201)

Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA‐VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Induction chemotherapy in fit de novo acute myeloid leukaemia (AML) patients has historically combined an anthracycline with standard‐dose cytarabine (‘7 + 3’) despite complete response (CR) rates of 50%–70%. In May 2023, our institution adopted the utilization of cladribine, cytarabine, idarubicin and venetoclax (CLIA‐VEN) for intensive ...
Benjamin J. Lee, Shawn P. Griffin, Jean Doh, Anthony Quach, Yujiao Sun, Piyatida Chumnumsiriwath, Stefan O. Ciurea, Jorge Ramos‐Perez, Polina Bellman, Deepa Jeyakumar, Piyanuch Kongtim, Kiran Naqvi   +11 more
wiley   +1 more source

Prognostic role of PET/CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International SEARCH for CAYAHL Group

British Journal of Haematology, EarlyView.
A visual overview of the key findings from the 35 papers included in this systematic review evaluating the use of PET volumetric parameters in children, adolescents and young adults with Hodgkin lymphoma. Summary In adults with classic Hodgkin lymphoma (cHL), metabolic tumour volume (MTV) is valuable for risk stratification.
S. Claire Gowdy, Jamie E. Flerlage, Jennifer Seelisch, Monica Palese, Tyler Bradshaw, Sharon M. Castellino, Steve Cho, Karin Dieckmann, Bradford S. Hoppe, Scott Howard, Kara M. Kelly, Lars Kurch, Hollie A. Lai, Egesta Lopci, John T. Lucas Jr., Christine Mauz‐Körholz, Kathleen M. McCarten, Neeta Pandit‐Taskar, Heiko Schöder, Jonas Steglich, Dietrich Stoevesandt, Stephan D. Voss, Sarah A. Milgrom   +22 more
wiley   +1 more source

Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy [PDF]

, 2017
Adjuvant therapy has improved the survival of women with early breast cancer (BC). Meta-analyses suggest that anthracycline-based regimens reduced the annual BC death rate by ∼40% in women below the age of 50 and 20% in older women. Novel agents designed
De Laurentiis, M., Ewer, M. S., Ewer, S. M., Harbeck, N., Suter, T. M.   +4 more
core  

Frontline ATRA‐ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG‐APL2017 Trial

Cancer Science, EarlyView.
FBMTG‐APL2017: First prospective multicenter trial evaluating frontline ATRA‐ATO therapy for newly diagnosed APL in Japan, encompassing both low–intermediate (n = 65) and high‐risk (n = 16) patients. Excellent outcomes (95% CR, 94% 3‐year DFS) with comparable efficacy between risk groups (DFS: 97% vs.
Ken Takase, Tomohiko Kamimura, Takuro Kuriyama, Takahito Tokuyama, Hideho Henzan, Yoshikane Kikushige, Ilseung Choi, Yutaka Imamura, Akio Mori, Shuki Ohya, Noriaki Kawano, Koji Yonemoto, Mine Harada, Koichi Akashi, Toshihiro Miyamoto   +14 more
wiley   +1 more source

Multiplexed Transcriptomics for Screening Drug Combinations and Defining the Mechanism of Action of HCC Therapeutics at Single‐Cell Resolution

Cell Proliferation, EarlyView.
We designed a framework for screening clinical drug combinations with anti‐hepatocellular carcinoma (HCC) activity, comprising four parts: primary screening, single‐cell screening, functional validation, and mechanism research. High‐throughput single‐cell screening identifies HY (HHT and YM155) as a potent anti‐HCC drug combination, validated by in ...
Mengmeng Jiang, Haide Chen, Guoxia Wen, Yuqing Mei, Wenzhao Zhou, Bin Xu, Tingyue Zhang, Guangyan Li, Junqing Wu, Xiaoping Han, Xudong Fu, Guoji Guo, Jingjing Wang   +12 more
wiley   +1 more source

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

European Journal of Haematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients.
Mamdouh Skafi, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Fortunato Morabito, Enrica Antonia Martino, Massimo Gentile   +12 more
wiley   +1 more source

Biphenyl Inhibitors of Carbonyl Reductase [PDF]

, 2012
Compositions of matter and methods of treating cancer patients may prevent or limit cardiotoxicity during or after chemotherapy, and/or may prevent or lower resistance to anthracycline drugs, both of which are believed to be caused by the human enzyme ...
Charlier, Henry A., Ewing, Christopher K.   +1 more
core   +1 more source

‘You can't have an ego in this game’: A simulation primed qualitative inquiry of team reflection in paediatrics

Medical Education, EarlyView.
Abstract Introduction Acute care paediatric teams face ambiguous, dynamic patient care situations that demand adaptability to avoid patient harm. Team huddles and adaptation processes have shown promise in mitigating risk and reducing harm. One team process that may occur in huddles is team reflection (TR), defined as a team's capacity to consciously ...
Rustin Meister, Mary E. McBride, Jan B. Schmutz, Mark Adler, Walter Eppich   +4 more
wiley   +1 more source

Exercise prehabilitation for brain health and sensory–cognitive function: Mechanistic insights into brain–body interactions

Experimental Physiology, EarlyView.
Abstract This mini review article presents a novel hypothesis for extending exercise prehabilitation into the domains of brain health and cognition. Whilst prehabilitation has been gaining popularity in cancer treatment, conferring significant positive benefits to numerous physiological indicators, including post‐operative infection and hospital length
Helen E. Nuttall, Daren Subar, Christopher J. Gaffney   +2 more
wiley   +1 more source

Suivi cardiaque des patients oncologiques pédiatriques après une chimiothérapie cardiotoxique [PDF]

, 2014
1.1 Introduction : Les anthracyclines (comme la doxorubicine) sont communément utilisées pour le traitement des leucémies, lymphomes et autres tumeurs malignes de l'enfant. Leur utilisation est cependant limitée par leur cardiotoxicité.
FEHLMANN, J.
core